Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company, today announced that Dr. Peter Wrighton-Smith, Chief Executive Officer, is scheduled to present at the following investor conferences this week.
OXFORD, United Kingdom and MARLBOROUGH, Mass., (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company, today announced that Dr. Peter Wrighton-Smith, Chief Executive Officer, is scheduled to present at the following investor conferences this week.
- Evercore ISI HealthCONx Conference on Tuesday, November 27, 2018 at 2:45 p.m. ET. The conference will be held at the Boston Harbor Hotel in Boston.
- 30th Annual Piper Jaffray Healthcare Conference on Wednesday, November 28, 2018 at 2:00 p.m. ET. The conference will be held at the Lotte New York Palace in New York City.
A live audio webcast of the fireside chat at the Piper Jaffray Conference on Wednesday, November 28 will be available online from the investor relations page of the Company’s corporate website at www.oxfordimmunotec.com. A webcast replay will be available approximately 24 hours after the live presentation and will be archived on the website for approximately 90 days.
About Oxford Immunotec
Oxford Immunotec Global PLC is a global, high-growth diagnostics company focused on developing and commercializing proprietary assays for immunology and infectious disease. The Company’s T-SPOT®.TB test has been approved for sale in over 50 countries, including the United States, where it has received pre-market approval from the Food and Drug Administration, Europe, where it has obtained a CE mark, as well as Japan and China. The Company is headquartered near Oxford, U.K. and in Marlborough, MA. Additional information can be found atwww.oxfordimmunotec.com.
T-SPOT and the Oxford Immunotec logo are trademarks of Oxford Immunotec Ltd.
CONTACTS:
For Media and Investor Inquiries:
Karen Koski
VP, Strategy and Investor Relations
Oxford Immunotec
Tel: +1 (508) 556-1377
